L. Arribillaga

发表

Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein.

J. Prieto, J. Lasarte, A. Zabaleta, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.

Lieping Chen, J. Prieto, I. Melero, 2005, Vaccine.

The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in mice

V. Garrido, I. Farran, I. Lasa, 2012, Veterinary Research.

Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin

J. Prieto, C. Leclerc, P. Berraondo, 2012, International journal of cancer.

Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses.

J. Prieto, C. Leclerc, J. Lasarte, 2012, Vaccine.

Vaccine Efficacy in Mice Regulatory T Cell Activity and Improves A Peptide Inhibitor of FOXP3 Impairs

J. Prieto, J. Lasarte, J. Riezu-Boj, 2010 .

A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine‐induced liver damage

P. Boya, J. Prieto, J. Lasarte, 2003 .

A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage.

P. Boya, J. Prieto, J. Lasarte, 2003, Hepatology.

The Extra Domain A from Fibronectin Targets Antigens to TLR4-Expressing Cells and Induces Cytotoxic T Cell Responses In Vivo1

J. Prieto, C. Leclerc, S. Hervás-Stubbs, 2007, The Journal of Immunology.

Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein.

J. Prieto, J. Lasarte, J. Riezu-Boj, 2009, Journal of hepatology.

T and B cell responses to multivalent prime-boost DNA and viral vectors vaccine combinations against hepatitis C virus in non-human primates

B. Bartosch, F. Cosset, J. Heeney, 2016 .

Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses

J. Prieto, I. Melero, A. Arina, 2003, Journal of Virology.

Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus.

J. Prieto, Á. Vales, J. Lasarte, 2002, Vaccine.

Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.

J. Prieto, J. Lasarte, J. Esteban, 2007, Antiviral research.

The Extra Domain A from Fibronectin Targets Antigens to TLR4-Expressing Cells and Induces Cytotoxic T Cell Responses In Vivo1

J. Prieto, C. Leclerc, S. Hervás-Stubbs, 2007, The Journal of Immunology.

CD137/CD137 Ligand in Tumor and Viral Immunotherapy

I. Melero, I. Tirapu, E. Huarte, 2006 .

[The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].

J. Prieto, I. Melero, J. Pérez-Gracia, 2006, Anales del sistema sanitario de Navarra.

Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis.

J. Lasarte, J. Riezu-Boj, P. Sarobe, 2011, Cytokine.

A Peptide Inhibitor of FOXP3 Impairs Regulatory T Cell Activity and Improves Vaccine Efficacy in Mice

J. Prieto, J. Lasarte, J. Riezu-Boj, 2010, The Journal of Immunology.

CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination 1

J. Prieto, I. Melero, J. Lasarte, 2003, The Journal of Immunology.

A Fusion Protein between Streptavidin and the Endogenous TLR4 Ligand EDA Targets Biotinylated Antigens to Dendritic Cells and Induces T Cell Responses In Vivo

J. Prieto, J. Lasarte, P. Sarobe, 2013, BioMed research international.

Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens

P. Romero, J. Carrascosa, S. Hervás-Stubbs, 2020, Journal for immunotherapy of cancer.

The extradomain A of fibronectin (EDA) combined with poly(I:C) enhances the immune response to HIV-1 p24 protein and the protection against recombinant Listeria monocytogenes-Gag infection in the mouse model.

V. Garrido, J. Lasarte, M. Grilló, 2012, Vaccine.

T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates

B. Bartosch, F. Cosset, J. Heeney, 2016, Gene Therapy.